Skip to main content

Table 4 Session product characteristics’ effects on symptom relief when using inhaled, dried Cannabis flower and treating cannabinoid measurements as continuous variables

From: The effectiveness of inhaled Cannabis flower for the treatment of agitation/irritability, anxiety, and common stress

  Overall Sample Agitation/irritability Anxiety Stress
(1) (2) (3) (4)
THC (%/dry wt.) − 0.020*** (0.006) 0.006 (0.018) − 0.024** (0.008) − 0.021* (0.009)
CBD (%/dry wt.) − 0.002 (0.009) 0.012 (0.015) − 0.001 (0.010) − 0.001 (0.012)
C. indica − 0.014 (0.104) − 0.209 (0.215) 0.033 (0.133) 0.018 (0.169)
C. sativa 0.215 (0.111) 0.162 (0.209) 0.222 (0.127) 0.250 (0.166)
Pipe 0.093 (0.256) 0.499 (0.653) − 0.385 (0.213) 0.498 (0.409)
Vape 0.135 (0.274) 0.708 (0.664) − 0.222 (0.268) 0.492 (0.406)
Session length (min) − 0.007*** (0.001) − 0.005* (0.002) − 0.007*** (0.001) − 0.008*** (0.001)
Baseline symptom intensity − 0.662*** (0.040) − 0.694*** (0.071) − 0.608*** (0.069) − 0.669*** (0.052)
Constant 0.281 (0.296) − 0.801 (0.744) 0.639 (0.379) − 0.058 (0.437)
Number of sessions 2306 422 998 886
Number of users 670 206 441 360
  1. Each column represents a separate regression. The outcome is the difference between the lowest reported symptom level within 4 h of initiating the session and the starting symptom level. The first column reports results for the whole sample, while columns 2 to 4 distinguish between specific distress-related symptoms reported. C. indica and C. sativa are relative to hybrid strains, and pipe and vape are relative to joint. All regressions are estimated using a fixed effects model and control for session length and baseline symptom intensity. Standard errors, clustered at the individual user level, are shown in parentheses
  2. ***p < 0.001, **p < 0.01, *p < 0.05